In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.
Houman Ashrafian, managing partner at SV Health Investors, sat down with In Vivo to discuss insights for investment strategies and the future of biotech in the UK. Ashrafian is based in London and heads up the SV biotech team alongside managing partner Kate Bingham, who led the UK's vaccine effort last year as chair of the UK Vaccines Task Force.
“SV is deeply embedded in the innovation economy,” said Ashrafian of the venture firm, which has approximately $2.7 bn in...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
